Alpha-difluoromethylornithine (DFMO) inhibits the protooncogene ornithine decarboxylase (ODC) and is known to induce cell cycle arrest. However, the effect of DFMO on human neuroblastoma (NB) cells and the exact mechanism of DFMO-induced cell death are largely unknown. Treatment with DFMO in combination with SAM486A, an S-adenosylmethionine decarboxylase (AdoMetDC) inhibitor, has been shown to enhance polyamine pool depletion. Therefore, we analysed the mechanism of action of DFMO and/or SAM486A in two established MYCN-amplified human NB cell lines. DFMO and SAM486A caused rapid cell growth inhibition, polyamine depletion, and G 1 cell cycle arrest without apoptosis in cell lines LAN-1 and NMB-7. These effects were enhanced with combined inhibitors and largely prevented by cotreatment with exogenous polyamines. The G 1 cell cycle arrest was concomitant with an increase in cyclin-dependent kinase inhibitor p27 Kip1 . In a similar fashion, DFMO and DFMO/SAM486A inhibited the phosphorylation of the G 1 /S transition-regulating retinoblastoma protein Rb at residues Ser795 and Ser807/811. Moreover, we observed a dramatic decrease in MYCN protein levels. Overexpression of MYCN induces an aggressive NB phenotype with malignant behavior. We show for the first time that DFMO and SAM486A induce G 1 cell cycle arrest in NB cells through p27
Introduction
Many studies over the years have demonstrated a role for polyamines in tumor cell growth, and the associated increase in biosynthetic enzyme activities (e.g. ornithine decarboxylase (ODC) and S-adenosylmethionine decarboxylase (AdoMetDC)) in tumor tissues relative to surrounding normal tissues renders a rationale for targeted drug intervention (Pegg, 1988; McCann and Pegg, 1992; Davidson et al., 1999; Meyskens and Gerner, 1999; Levin et al., 2000 Levin et al., , 2003 Takahashi et al., 2000; Bachmann, 2004) .
The proto-oncogene ODC is a key enzyme in polyamine biosynthesis and catalyses the conversion of ornithine (Orn) to putrescine (Put). The latter is further converted to the higher polyamines spermidine (Spd) and spermine (Spm), all of which have been implicated in tumor cell growth. A second rate-limiting enzyme in polyamine biosynthesis is AdoMetDC, which provides the aminopropyl donor decarboxylated S-adenosylmethionine and is required for the sequential conversions of Put to Spd and Spm. Specific inhibitors for both ODC and AdoMetDC are available and have been used in polyamine-related studies (Supplementary information). Alpha-difluoromethylornithine (DFMO, also known as Eflornithine) (Metcalf et al., 1978) is a synthetic suicide inhibitor of ODC, which has been intensively evaluated in human clinical trials as an anticancer and chemopreventive agent (Porter et al., 1992; Meyskens and Gerner, 1999; Levin et al., 2000 Levin et al., , 2003 Carbone et al., 2001; Fabian et al., 2002) . SAM486A (also known as CGP48664), a derivative of the first-generation AdoMetDC inhibitor mitoguazone (MGBG), exerts potent and specific inhibition of AdoMetDC (Regenass et al., 1994; Svensson et al., 1997) . Its efficacy has been assessed in various cancer cells and animal systems (Regenass et al., 1994; Dorhout et al., 1995; Svensson et al., 1997) , and has been evaluated in Phase I and Phase II human clinical trials (Eskens et al., 2000; Paridaens et al., 2000; Siu et al., 2002; Pless et al., 2004; van Zuylen et al., 2004) . Neuroblastoma (NB) is the most common extracranial tumor of childhood, with approximately 700 new cases per year in the United States. While many infants experience complete regression of primary tumors and even metastatic disease, older children are often confronted with NB metastases that are aggressive and respond poorly to even the most intense multi-component drug regimens. MYCN proto-oncogene amplification occurs in approximately 20% of primary NB tumors, and is strongly associated with advanced stage disease, rapid tumor progression, and poor prognosis (Brodeur et al., 1984; Seeger et al., 1985; Brodeur, 2003) . While DFMO has been shown to induce growth inhibition and differentiation in NB cells (Chapman, 1980; Melino et al., 1988; Melino et al., 1991) , no related NB studies exist with SAM486A alone or combined with DFMO. To our knowledge, these two inhibitors have never been considered for human NB clinical trials.
This study was designed (1) to explore the therapeutic potential of DFMO and SAM486A in human NB cells, and (2) to examine the underlying molecular mechanisms by which these inhibitors suppress cell growth. We initially showed that several NB cell lines are inhibited in a dose-dependent manner. Of those, we selected two cell lines (LAN-1 and NMB-7) for further analyses, both of which are MYCN-amplified and mutated in the tumor suppressor protein p53 (Davidoff et al., 1992; Goldman et al., 1996; Tweddle et al., 2003) . Our findings showed that both inhibitors alone, or in combination, depleted polyamine pools to various degrees and caused severe growth inhibition associated with G 1 cell cycle arrest as early as 2 days after treatment. Significant morphological changes in the actin cytoskeleton, an increase in cyclin-dependent kinase inhibitor p27
Kip1
, hypophosphorylation of Rb, and downregulation of MYCN accompanied these effects. The inhibitor-induced G 1 arrest in LAN-1 and NMB-7 cells occurred in the absence of p53, since the tested cell lines are p53 deficient. The fact that DFMO and SAM486A effectively and rapidly inhibited the growth of the MYCNamplified LAN-1 and NMB-7 cells provides a strong rationale for their therapeutic use in patients with progressive or relapsed NB tumors, which often show MYCN amplification and p53-associated chemoresistance (Tweddle et al., 2001 (Tweddle et al., , 2003 with poor prognostic outcome.
Results

Expression of ODC, AdoMetDC, and MYCN in NB cells
To characterize the NB cell lines LAN-1 and NMB-7, we verified the presence of ODC, AdoMetDC, and MYCN at the RNA level using reverse-transcriptasepolymerase chain reaction (RT-PCR). Total RNA was isolated from subconfluent monolayer cell cultures and equal amounts of RNA were reverse-transcribed into cDNA and then analysed by PCR using specific DNA primers. ODC, AdoMetDC, and MYCN mRNAs were expressed in both cell lines, as indicated by the PCR products of expected sizes at 400, 450, and 220 bp, respectively ( Figure 1a ). These results confirm that LAN-1 and NMB-7 cells produce mRNA for both target enzymes and that both cell lines are of the MYCN-amplified NB subtype.
To determine the presence of ODC, AdoMetDC, and MYCN at the protein level, cell lysates containing equal amounts of protein were analysed by Western blotting. ODC (53 kDa) and processed AdoMetDC a chain (31 kDa) proteins were detected at the expected size in LAN-1 and NMB-7 cells (Figure 1b , left and middle panels), using an ODC-specific antibody and an AdoMetDC-recognizing rabbit serum, respectively. As the latter interacted with several other proteins, we verified the presence of AdoMetDC in LAN-1 cells treated with 5 mM DFMO and 10 mM SAM486A. The treatment of cells with both polyamine inhibitors for 3 days strongly induced AdoMetDC protein expression, as indicated by an increase of the 31 kDa band, while the intensity of a second band at 75 kDa did not change ( Figure 1c ). The MYCN protein (67 kDa) was also strongly expressed in LAN-1 and NMB-7 cells (Figure 1b, right panel) .
The presence and functionality of ODC and AdoMetDC was further demonstrated by measuring their respective enzyme activities in lysates of LAN-1 and NMB-7 cells harvested at early (day 1), mid (day 2), and late (day 3) log phase. As shown in Figure 1d (ODC) and Figure 1e (AdoMetDC), enzyme activities were detected in both cell lines. Specific activities were highest during the early-to-mid log growth phase, with a marked decline in activity on day 3. Protein concentrations from cell lysates on days 1, 2, and 3 indicated logarithmic cell growth (not shown). These results together clearly show that (1) mRNAs for ODC, AdoMetDC, and MYCN are present in LAN-1 and NMB-7 cells, (2) mRNAs are properly translated into proteins, and (3) ODC and AdoMetDC are functionally active enzymes.
Effects of DFMO and SAM486A on ODC and AdoMetDC activities and polyamine pools Next, we determined the effects of DFMO and SAM486A on enzymatic activities of ODC and AdoMetDC in inhibitor-treated cells. Cell lines LAN-1 and NMB-7 were left untreated (control) or treated with 5 mM DFMO, 10 mM SAM486A, or the combination of both inhibitors for 2 days (mid-log phase) and enzyme activities were measured in cell lysates. In comparison with untreated cells, the ODC enzyme activity was lower after DFMO treatment and was further decreased by combined inhibitor treatment, while SAM486A alone increased ODC activity (Table 1) . Preincubation of extracts from untreated or DFMO-treated cells with 100 mM DFMO resulted in a complete loss of ODC activity (data not shown), indicating that the residual ODC activity represents a new steady state in the presence of the inhibitor rather than DFMO-resistant ODC protein. Under identical experimental conditions, AdoMetDC activity was determined. In contrast to ODC, we found that treatment with DFMO, SAM486A, or the combination of both inhibitors increased AdoMetDC activity (Table 1) . SAM486A acts as a competitive inhibitor of AdoMetDC in the cell and is capable of stabilizing the enzyme (Svensson et al., 1997) , as shown in Figure 1c . Therefore, AdoMetDC activity is elevated in the in vitro assay of SAM486A-treated cells because dilution of the cellular contents to prepare the cytosolic lysate reduces the concentration of SAM486A below the level necessary for inhibition and reveals the stabilization of the enzyme. Sequential dilution and concentration of cell lysates to remove the residual inhibitor further increased the measured AdoMetDC activity nearly 100-fold in SAM486A-treated cells (not shown). This contrasts with the irreversible inhibition of ODC by the suicide inhibitor DFMO, which is readily apparent in the in vitro assay. The further increase in AdoMetDC activity observed in cells Enzyme activities of ODC (d) and AdoMetDC (e) were determined in LAN-1 and NMB-7 cell lysates in a time-course study. Cells (1 Â 10 5 cells/ml) were seeded in 10 cm culture dishes and harvested after 1, 2, and 3 days. Specific enzyme activities are expressed as pmol CO 2 /30 min/mg protein. Each sample was measured in duplicate and data represent the mean of three independent experiments7s.d. To study the effects of inhibitors on intracellular polyamine pools, LAN-1 and NMB-7 cells were treated with DFMO, SAM486A, or both inhibitors combined, for 2 and 3 days ( Table 2 ). Inhibition of ODC by DFMO decreased Put and Spd pools in both cell lines, while Spm pools decreased only slightly. Inhibition of AdoMetDC with SAM486A dramatically increased Put levels in both cell lines, indicating an efficient blockade in the polyamine biosynthetic pathway between Put and Spd, and reduced Spd and Spm levels. Combined inhibition of both enzymes decreased polyamine pools to various degrees, and exogenous supplementation of Spd (10 mM) to cell cultures led to a substantial increase in Spd. These observations are comparable with trends seen in other cell types (Kramer et al., 1989 (Kramer et al., , 2001 Svensson et al., 1997) . In untreated control cells, the levels of Put and Spd decreased during exponential cell growth (day 0 to day 3), which is also consistent with a decrease in ODC and AdoMetDC enzyme activities (Figure 1d and e). Spm levels decreased in untreated LAN-1 cells and remained the same in NMB-7 cells (Table 2) .
Effects of DFMO and SAM486A on cell growth and morphology
To determine the effects of DFMO and SAM486A on the growth of NB cells, LAN-1 and NMB-7 cells were exposed to 5 mM DFMO, 10 mM SAM486A, or the combination of both inhibitors for 3 days, and the cell number was determined. As depicted in Figure 2a , LAN-1 and NMB-7 cell growth slowed substantially, and the combination of both inhibitors led to near-total cessation of cell growth after 3 days. Exogenous supplementation of cell cultures with Spd (10 mM) clearly alleviated the growth-inhibitory effects, thus indicating that the inhibition of cell growth is due to polyamine pool depletion. Identical treatment of cells with 0.5 mM DFMO and 1 mM SAM486A (alone, and in combinations) resulted in dose-dependent growth inhibition (not shown). Moreover, we showed that DFMO and SAM486A inhibited the growth of several other NB cell lines including SK-N-SH, SH-SY5Y (both MYCNnonamplified and p53 wild type), LAN-5, and IMR-32 (both MYCN-amplified and p53 wild type) in a dosedependent manner (not shown).
The observed growth inhibition of LAN-1 and NMB-7 cells was accompanied by dramatic alterations in cell morphology ( Figure 2b ). After 3 days of treatment with 5 mM DFMO, the triangular-shaped LAN-1 cells changed into spindle-like cells with neurite-like extensions. Under identical treatment, NMB-7 cells formed large polynucleate cell aggregates with only very short extensions. Treatment of these two cell lines with 10 mM SAM486A resulted in similar cell aggregates, but in the absence of neurite-like extensions. The combination of both inhibitors led to a mixed-type cell morphology, and supplementation of these cells with Spd (10 mM) at the beginning of the experiment alleviated the inhibitor effects, producing normal, triangular-shaped cells comparable to untreated control cells.
To further study these morphological changes, LAN-1 and NMB-7 cells were treated with 5 mM DFMO, 10 mM SAM486A, or the combination of both inhibitors, and the actin cytoskeleton was visualized using phalloidin. Concomitant staining with 4 0 ,6-diamidino-2-phenylindole (DAPI) allowed the visualization of cell nuclei. As shown in Figure 3 , the treatment with DFMO and/or SAM486A clearly disturbed the actin cytoskeleton in both cell lines. Furthermore, the DAPI-stained nuclei reveal the presence of polynucleate aggregates in both cell lines, which confirms that the large cell aggregates seen in Figure 2b are indeed composites of several cells.
In summary, these data show that in NB cells, DFMO and SAM486A cause rapid growth inhibition and induce morphological changes within 3 days. Similar effects were already apparent after 1-2 days (not shown). By comparison, the treatment of human melanoma cells (MALME-3) with polyamine inhibitors required more extensive incubation times (8-12 days) and led to less obvious rearrangements in cell structures (Kramer et al., 2001) . Furthermore, human ovarian Prolonged cell growth inhibition after combined treatment with DFMO and SAM486A
To examine whether the combined treatment with DFMO and SAM486A produces NB cell populations which lose their proliferative capacity permanently, LAN-1 and NMB-7 cells were either left untreated (control) or treated with 5 mM DFMO plus 10 mM SAM486A, and cell numbers were determined after 3 days ( Figure 4 ). As expected, the growth of cells treated with both inhibitors was strongly suppressed. On day 3 of the experiment, cells were washed free of inhibitors with PBS, suspended in new medium (NM) without inhibitors, and seeded again at the initial cell density. While the untreated LAN-1 and NMB-7 cells grew normally and reached similar cell densities after an additional 3 days (day 6 of the experiment), the initially treated LAN-1 and NMB-7 cells resumed proliferation only slowly and reached about 30 and 58% of control cell growth, respectively, on day 10 of the experiment (Figure 4 ). This result indicates that the combined polyamine inhibitor treatment leads to sustained growth arrest in both MYCN-amplified NB cell lines as, even after removal of inhibitors, their proliferative capacity is slowly and only partially restored. Similar experiments using DFMO and SAM486A individually revealed that the sustained growth arrest was primarily due to the action of DFMO and not SAM486A (not shown).
Effects of DFMO and SAM486A on cell cycle distribution
Depletion of polyamines has previously been shown to cause G 1 cell cycle arrest in cancer cells (Ray et al., 1999; Kramer et al., 2001; Singh et al., 2001) . To investigate whether the observed growth inhibition of NB cells is due to the interference with cell cycle kinetics, LAN-1 and NMB-7 cells were treated with 5 mM DFMO, 10 mM SAM486A, or the combination of both inhibitors, harvested, and stained with propidium iodide (PI) on days 2 and 3 of the experiment. As shown in Table 3 , both inhibitors individually produced changes in the cell cycle distribution at days 2 and 3 of the experiment, Regulation of p27 Kip1 , Rb, and MYCN by polyamine inhibitors CJ Wallick et al as indicated by the accumulation of cells in G 1 and a reduction of cells in S phase and in G 2 /M phase. This profile, which is typical for cell cycle arrest at G 1 , was enhanced by the combination of both inhibitors, with the majority of cells in G 1 (B71-73%), a reduced number of cells in S phase (B20-28%), and a small portion in G 2 /M (B2-7%). Cotreatment with both inhibitors plus Spd (10 mM) prevented G 1 arrest (Table 3) , which is in agreement with the growth inhibition data shown in Figure 2 . The polyamine depletion-induced G 1 cell cycle arrest did not involve apoptosis, as judged by (i) the absence of typical morphological changes such as nuclear condensation, membrane blebbing, and loss of cell adherence (Figures 2 and 3) , (ii) the absence of PARP cleavage (not shown), and (iii) the lack of an apoptosis-associated G 1 subpeak (Table 3) . Similar observations were previously reported using normal rat intestinal epithelial cells (IEC-6) (Ray et al., 1999) .
Strong and rapid changes in cell cycle regulatory proteins p27 Kip1 , Rb, and MYCN
To this end, our data showed that the treatment of LAN-1 and NMB-7 cells with DFMO and/or SAM486A inhibits polyamine-dependent cell growth and causes G 1 cell cycle arrest, and these effects could be largely prevented by the addition of Spd. To further investigate the mechanism that regulates G 1 arrest in LAN-1 and NMB-7 cells, and to define the changes in associated protein responses, we studied the cell cyclerelated proteins p21
Waf1/Cip1
, p27
Kip1
, p53, Rb, and MYCN in NB cell lysates. We found that LAN-1 and NMB-7 cells treated with 5 mM DFMO increased endogenous levels of cdk inhibitor protein p27 Kip1 relative to untreated control cells after 2 days of treatment. This effect was enhanced on day 3 of the experiment and was further increased in the presence of both inhibitors (Figure 5a ). By comparison, treatment with 10 mM SAM486A alone did not increase p27 Kip1 levels. The result suggests that p27
Kip1 plays a role in the observed G 1 cell cycle arrest in NB cells (Table 3) , and that this effect is primarily due to the action of DFMO, and not SAM486A. To test for the presence of the cdk inhibitor protein p21
Waf1/Cip1 , identical experiments were conducted, but the protein could not be detected (not shown). Low levels of p21 Waf1/Cip1 in NB cells have been previously described (McKenzie et al., 2003) . Similarly, the tumor-suppressor protein p53 was not detected (not shown), which is in agreement with previous findings that cell lines LAN-1 and NMB-7 are p53 deficient. In contrast, p53 was readily expressed in identical Western blot control experiments and detected by immunofluorescence using the p53 wild-type cell line SK-N-SH (not shown).
The retinoblastoma protein Rb can be regulated through the action of p27 Kip1 . Rb phosphorylation reduces the levels of functional Rb/E2F repressor complexes and activates E2F-responsive promoters important for moving the cell through the G 1 /S phase of the cell cycle. To study the effects on Rb phosphorylation, LAN-1 and NMB-7 cells were treated with DFMO and/or SAM486A and analysed on days 1, 2, and 3 using two phospho-specific Rb (p-Rb) antibodies as well as an antibody which recognizes total Rb protein. As shown in Figure 5b , Rb was phosphorylated at residue Ser795 and residues Ser807/811 in untreated LAN-1 and NMB-7 cells, while the treatment with DFMO or the combination of DFMO and SAM486A resulted in strong hypophosphorylation of Rb on days 2 and 3 of the experiment. The effect of SAM486A alone was much less pronounced. Rb hypophosphorylation was further confirmed with total Rb showing a visible mobility shift from a hyperphosphorylated form (upper band) to a hypophosphorylated form (lower band). The treatment with both inhibitors for 3 days completely (&) or the presence () of 5 mM DFMO plus 10 mM SAM486A. On day 3, both untreated and treated cells were washed twice with PBS, reseeded in NM (solid black arrow) without inhibitors at the starting cell density (dashed black arrow), and the experiment was continued for an additional 7 days. Cell numbers were determined using a hemocytometer and trypan blue reagent, and each data point is representative of three separate determinations7s.d. dephosphorylated Rb and also decreased the total levels of Rb (Figure 5b ). Hypophosphorylation of Rb is a known consequence of p27
Kip1 induction, and this is in strong agreement with our findings. In summary, the results suggest that polyamine inhibitor-induced G 1 cell cycle arrest in MYCN-amplified NB cells is mediated by an increase in p27
Kip1 and subsequent hypophosphorylation of Rb.
Downregulation of MYCN expression either by antisense treatment or by retinoic acid (RA) has been shown to inhibit cell growth and/or induce neuronal differentiation of NB cells (Matsuo and Thiele, 1998; Galderisi et al., 1999 Galderisi et al., , 2003 Lu et al., 2003) . Therefore, we were curious to see whether DFMO and SAM486A also affect MYCN protein levels in LAN-1 and NMB-7 cells. As shown in Figure 5c , DFMO and both inhibitors in combination, and to a lesser extent SAM486A alone, decreased MYCN levels in both cell lines as early as day 1 and, most profoundly, on day 3 of the experiment. The quantification of data showed that both drugs combined reduced MYCN levels to 6% and 5% of controls in LAN-1 and NMB-7 cells, respectively.
Discussion
In the present paper, we investigated for the first time the effects of the clinically well-established polyamine inhibitors DFMO and SAM486A in two MYCNamplified NB cell lines. We found that both inhibitors interfere with ODC and AdoMetDC enzyme activities, cause polyamine depletion, and, ultimately, disturb cell cycle progression at the G 1 /S transition, which leads to growth arrest. The combination of both inhibitors generally intensified these effects (Table 3 , Figures 2a and 5) . We also found that the growth inhibition of cells treated with a combination of DFMO and SAM486A was sustained even after removal of inhibitors, thus suggesting prolonged growth arrest (Figure 4) .
To further explore the underlying molecular mechanisms by which DFMO and SAM486A induce G 1 cell cycle arrest, we examined the expression patterns of cell cycle-associated proteins in response to inhibitor treatments. Most significantly, we found that the protein levels of p27
Kip1 sharply increased in the presence of DFMO alone or combined with SAM486A (Figure 5a ). Our results further showed that this increase in p27
Kip1 is tightly correlated with hypophosphorylation of Rb (Figure 5b ). Since Rb is a known regulator of G 1 /S transition, it is conceivable that the polyamine inhibitorinduced G 1 cell cycle arrest in LAN-1 and NMB-7 cells is regulated by Rb hypophosphorylation in response to p27 Kip1 . Similarly, it was shown that p27
Kip1 is a key mediator of RA-induced growth arrest in NB cells (Matsuo and Thiele, 1998) . Our findings are also in partial agreement with results obtained with other cell systems, such as normal rat cells IEC-6 (Ray et al., 1999) , human breast cancer cells MDA-MB-468 (Singh et al., 2001) , and human melanoma cells MALME-3 (Kramer et al., 2001) . However, in those cell lines, polyamine inhibitor-induced G 1 arrest was primarily regulated by p21
Waf1/Cip1 and p53, while DFMO and DFMO/SAM486A in LAN-1 and NMB-7 cells increased p27
Kip1 in the absence of both p21 Waf1/Cip1 and p53. Furthermore, in contrast to the rapid growth inhibition observed in NB cells (Figure 2 ), IEC-6 and MALME-3 cells required treatments of up to 10 days with DFMO (Ray et al., 1999) , respectively, and showed almost no alterations in cell morphology. This suggests that DFMO and SAM486A are more potent in NB cells and, possibly, also more successful in killing NB tumors. Downregulation of MYCN is of great interest with regard to developing advanced NB therapies. It has previously been shown that DFMO blocks the expression of c-Myc (Tabib and Bachrach, 1994) and these findings are extended by our own results, which show strong downregulation of the c-Myc-related protein MYCN in response to DFMO or DFMO/SAM486A (Figure 5c ). It has also been shown that MYCN can regulate p27
Kip1 in NB cells by targeting p27 Kip1 to the proteasome (Nakamura et al., 2003) , and it is therefore possible that the observed increase in p27
Kip1 is in response to a decrease in MYCN. Figure 6 shows the possible involvement of polyamines in the regulation of p27 Kip1 , Rb, and MYCN in LAN-1 and NMB-7 cells based on our observations. The regulation of ODC by MYCN has been previously proposed (Lutz et al., 1996; Ben-Yosef et al., 1998; Lu et al., 2003) and is also subject to current investigations in our laboratory. The precise mechanism by which polyamines regulate MYCN in NB cells remains to be further clarified.
In conclusion, our findings provide new insights into the regulation of ODC, AdoMetDC, and polyamines in NB cells. Furthermore, we show for the first time that the proteins p27 Kip1 , Rb, and MYCN play a key role in polyamine inhibitor-induced G 1 cell cycle arrest in MYCN-amplified NB cells. Unlike DFMO and DFMO/ SAM486A, we found that SAM486A alone had almost no effect on p27 Kip1 , Rb, and MYCN despite its profound effects on polyamine pools, G 1 arrest, and NB cell growth and morphology. The reason for this is unclear. We suspect that other cell signaling molecules are involved in the observed SAM486A-induced growth arrest, which are yet to be identified. It is possible that the exceptionally high putrescine levels, which occur only in SAM486A-treated cells (Table 2) , may be the reason for the observed differences.
The presented results are in support of our hypothesis that the combined administration of DFMO and SAM486A provides an effective means for the treatment of NB tumors (Bachmann, 2004) . Our findings are particularly relevant because DFMO and SAM486A cause rapid and prolonged growth inhibition of two MYCN-amplified NB cell lines, which (1) are representative of MYCN-amplified tumors with aggressive behavior, and (2) are deficient in p53. Mutated p53 is often associated with relapsed and more progressive tumors, which circumvent p53-mediated apoptosis and exhibit chemoresistance (Hopkins-Donaldson et al., 2002) . Since DFMO and SAM486A have been recently evaluated in Phase III and Phase II human trials, respectively (Levin et al., 2003; Pless et al., 2004) , there is considerable information available regarding their concurrent side effects, pharmacokinetics, and maximum tolerated doses. Therefore, DFMO and SAM486A, possibly in combination with cytotoxic drugs at reduced doses, and concomitant with a strict polyamine-limited diet, should be considered for the treatment of late-stage NB patients with unfavorable outcome.
Materials and methods
Chemicals
The ODC inhibitor DFMO (Metcalf et al., 1978) and the AdoMetDC inhibitor SAM486A (Regenass et al., 1994; Svensson et al., 1997) were provided by Dr Patrick Woster (Wayne State University, MI, USA) and Novartis (Basel, Switzerland), respectively. Spd and aminoguanidine were obtained from Sigma Chemical Co. (St Louis, MO, USA).
Cell lines and treatment of cultured cells
Human NB cell lines were provided by Dr Robert Seeger (LAN-1; University of California, Los Angeles, CA, USA), Dr Nai-Kong Cheung (NMB-7; Memorial Sloan-Kettering Cancer Center, NY, USA), and the American Type Culture Collection (SK-N-SH; ATCC, Manassas, VA, USA). Cells were maintained in RPMI 1640 (Biosource, Rockeville, MD, USA) containing 10% heat-inactivated fetal bovine serum (FBS) (Invitrogen, Carlsbad, CA, USA), penicillin (100 IU/ml) and streptomycin (100 mg/ml). If cells were treated with exogenous Spd, 1 mM of aminoguanidine was included as an inhibitor of serum polyamine oxidation. Cells were seeded 2-3 h before treatment with 5 mM DFMO and/or 10 mM Proposed interplay between polyamines and cell cycle regulatory proteins in MYCN-amplified NB cells. Polyamines play a key role in cell cycle regulation (Wallace et al., 2003) , but proteins which are directly regulated by polyamines are still poorly defined.
High polyamine titers promote cell cycle progression and cell proliferation, presumably via the blocking of cyclin-dependent kinase inhibitor p27 Kip1 , which leads to hyperphosphorylation of retinoblastoma protein Rb. The blockade of polyamine biosynthesis with specific inhibitors DFMO and SAM486A leads to G 1 cell cycle arrest in response to p27
Kip1 upregulation and subsequent hypophosphorylation of Rb. MYCN is strongly downregulated in response to polyamine depletion and is known to regulate p27 Kip1 and ODC gene expression in NB cells
Regulation of p27
Kip1 , Rb, and MYCN by polyamine inhibitors CJ Wallick et al SAM486A and analysed after 1, 2, and/or 3 days. For growth inhibition, polyamine pool, and cell cycle studies, 10 mM Spd was added together with inhibitors, and cells were assayed on days 2 and/or 3.
RT-PCR analysis
Total RNA was isolated from control or treated NB cells using the RNeasy mini kit (Qiagen Inc., Valencia, CA, USA). The cDNA synthesis and standard RT-PCR analysis were performed with DNAse-treated total RNA using the following primer sets: ODC-fwd, 5 0 -gtatgctgctaataatggag-3 0 ; ODC-rev,
0 -ccaacatgatctgggtcatcttctc-3 0 (loading control).
ODC and AdoMetDC activity assays
ODC and AdoMetDC enzyme activities were determined using a standard assay as previously reported (Coleman and Pegg, 1998; Shantz and Pegg, 1998) . In brief, NB cells were washed twice with ice-cold PBS and harvested in 50 mM sodium phosphate buffer (pH 7.2), 0.1 mM EDTA, 2.5 mM DTT, supplemented with 1 Â protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA). For the measurement of AdoMetDC activity, cells were harvested in the above buffer supplemented with 2.5 mM Put. Cells were lysed by three freeze/thaw cycles and cell lysates were prepared by centrifugation for 20 min at 14 000 r.p.m. and 41C. ODC activity was measured in a reaction mixture that contained 20 mM L-ornithine (47.70 mCi/mmol; NEN Life Science Products, Boston, MA, USA). AdoMetDC activity was assayed in a reaction mixture that contained 8.2 mM S-adenosyl-L-[carboxy-
14
C]methionine (58.0-61.0 mCi/mmol; Amersham Biosciences, Piscataway, NJ, USA) and 140.1 mM cold S-adenosylmethionine. Extracts from untreated or DFMO-treated LAN-1 cells were incubated in 100 mM DFMO for 30 min at 371C prior to the ODC activity assay to test for DFMO-resistant ODC. Untreated or SAM486A-treated LAN-1 extracts were assayed for AdoMetDC activity after multiple rounds of sequential dilution with harvest buffer, followed by concentration of the extract (Centricon YM-10, Millipore Corporation, Bedford, MA, USA) to remove the inhibitor. This process resulted in an approximately 400-fold dilution of the residual inhibitor in the extract without a significant change in the overall protein concentration.
Polyamine pool analysis
Intracellular polyamines were extracted from cell pellets as previously described (Gilbert et al., 1991) . In brief, cells were washed and centrifuged. After sonication and centrifugation, 250 ml of supernatant, 100 ml of saturated sodium carbonate, and 300 ml of 25 mg/ml dansyl chloride (5-dimethylaminonaphthalene-1-sulfonyl chloride) (Fluka, Switzerland) were mixed and analysed via reverse-phase HPLC using a C18 reverse-phase analytical column (Waters, Milford, MA, USA). The effluent from the column was monitored at 510 nm (excitation at 330 nm). Polyamine levels were determined using appropriate standards. The samples were normalized in 0.2 N sodium hydroxide and the amount of total protein per sample was measured using the Bradford assay (70). Polyamine levels are expressed as nmol per mg of total cellular protein.
Flow cytometry
Cell samples were stained with PI using the procedure described by Krishan (1975) and subjected to flow-cytometric analysis using a FACScan flow cytometry instrument (Becton Dickinson, San Jose, CA, USA). Cell cycle distribution was determined using the ModFit software.
Western blot analysis
Cell lysates were prepared in RIPA buffer (20 mM Tris-HCl, pH 7.5, 0.1% sodium lauryl sulfate, 0.5% sodium deoxycholate, 135 mM NaCl, 1% Triton X-100, 10% glycerol, 2 mM EDTA), supplemented with a protease inhibitor cocktail (Roche Molecular Biochemicals, Indianapolis, IN, USA) and phosphatase inhibitors sodium fluoride (NaF; 20 mM) and sodium vanadate (Na 3 VO 4 ; 0.27 mM). The total protein concentration was determined using the protein assay dye reagent from Bio-Rad Laboratories (Hercules, CA, USA). Cell lysates in SDS-sample buffer were either boiled for 5 min or incubated at room temperature for 60 min, and equal amounts of total protein analysed by 10% SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting using PVDF membranes. The antibodies used in this study are: mouse monoclonal p21
Waf1/Cip1 (sc-817), rabbit polyclonal p27 (Austin, TX, USA). The AdoMetDC-recognizing rabbit serum was described previously (Shantz et al., 1994) . Secondary antimouse and anti-rabbit antibodies (Amersham Biosciences, Piscataway, NJ), and secondary anti-goat antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were coupled to horseradish peroxidase (HRP). Proteins were detected using the ECL or ECL Plus reagents (Amersham Biosciences, Piscataway, NJ, USA) and Kodak BioMax XAR film (Fisher Scientific, Pittsburgh, PA, USA), and bands quantified using a Bio-Rad Fluor-S Multi Imager and Quantity One Quantitation Software, Version 4 (Bio-Rad Laboratories, Hercules, CA, USA).
Microscopy
Cells were grown in cell culture dishes, treated with inhibitors as described above and light micrographs were taken after 3 days using an inverted phase-contrast microscope (Nikon Diaphot, Nikon Corporation, Tokyo, Japan). To visualize the actin cytoskeleton, NB cells were grown on glass coverslips in 12-well plates and at the end of the treatment stained with Texas Red-X phalloidin according to the manufacturer's instructions (Molecular Probes, Eugene, OR, USA). Cells were washed, fixed in 3% p-formaldehyde for 10 min, and exposed to 0.1% Triton X-100 for 5 min. Fixed cells were washed again, blocked in 1% BSA/PBS for 30 min, and incubated with phalloidin for 20 min in the dark at room temperature. Washed coverslips were mounted using Vectashield s Mounting Medium with DAPI (Vector Laboratories, Inc., Burlingame, CA, USA) and samples analysed with an epifluorescence microscope (Zeiss Axioplan). 
